Evidence map›Paper›PMID 27933306›Full record

ArticleMolecular therapy. Methods & clinical development2016

Significant changes in endogenous retinal gene expression assessed 1 year after a single intraocular injection of AAV-CNTF or AAV-BDNF.

Chrisna J LeVaillant, Anil Sharma, Jill Muhling, Lachlan Pg Wheeler, Greg S Cozens, Mats Hellström, Jennifer Rodger, Alan R Harvey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Eurycomanone fromJournal of clinical biochemistry and nutrition · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Neural regeneration research · 2017
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Chrisna J LeVaillantSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia , Western Australia, Australia.
Anil SharmaSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia , Western Australia, Australia.
Jill MuhlingSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia , Western Australia, Australia.
Lachlan Pg WheelerSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia , Western Australia, Australia.
Greg S CozensSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia , Western Australia, Australia.
Mats HellströmSchool of Anatomy, Physiology, and Human Biology, The University of Western Australia, Western Australia, Australia; Department of Obstetrics and Gynecology, Laboratory for Transplantation and Regenerative Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jennifer RodgerSchool of Animal Biology, The University of Western Australia, Western Australia, Australia; Western Australian Neuroscience Research Institute, Western Australia, Australia.
Alan R HarveySchool of Anatomy, Physiology, and Human Biology, The University of Western Australia, Western Australia, Australia; Western Australian Neuroscience Research Institute, Western Australia, Australia.
University of Western Australia · AUPerron Institute for Neurological and Translational Science · AUUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Use of viral vectors to deliver therapeutic genes to the central nervous system holds promise for the treatment of neurodegenerative diseases and neurotrauma. Adeno-associated viral (AAV) vectors encoding brain-derived neurotrophic factor (BDNF) or ciliary derived neurotrophic factor (CNTF) promote the viability and regeneration of injured adult rat retinal ganglion cells. However, these growth-inducing transgenes are driven by a constitutively active promoter, thus we examined whether long-term AAV-mediated secretion of BDNF or CNTF affected endogenous retinal gene expression. One year after the intravitreal injection of AAV-green fluorescent protein (GFP), bi-

Identifiers

PMID27933306
PMCPMC5142514
OpenAlexW2560243645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.